Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F21%3A73610012" target="_blank" >RIV/61989592:15110/21:73610012 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.3390/diagnostics11061050" target="_blank" >https://doi.org/10.3390/diagnostics11061050</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/diagnostics11061050" target="_blank" >10.3390/diagnostics11061050</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course

Popis výsledku v původním jazyce

Somatostatin analogues are considered to be the first line of treatment in acromegaly. Somatostatin analogues of the first generation mainly target the somatostatin receptor (SSTR) subtype 2 and have been proven efficient in the majority of patients with acromegaly. Pasireotide was the first somatostatin analogue also substantially targeting the SSTR subtype 5. An efficient drug for Cushing’s disease tailored to suboptimal-responding patients with acromegaly then became available. We immunohistochemically investigated SSTR subtypes expression in pituitary adenomas from operated acromegaly patients with clinical relapse and a complicated clinical course. Patients received pasireotide in the course of their disease. The predictive value of SSTR subtypes immunhistochemical analysis for the therapeutic response is discussed.

Název v anglickém jazyce

Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course

Popis výsledku anglicky

Somatostatin analogues are considered to be the first line of treatment in acromegaly. Somatostatin analogues of the first generation mainly target the somatostatin receptor (SSTR) subtype 2 and have been proven efficient in the majority of patients with acromegaly. Pasireotide was the first somatostatin analogue also substantially targeting the SSTR subtype 5. An efficient drug for Cushing’s disease tailored to suboptimal-responding patients with acromegaly then became available. We immunohistochemically investigated SSTR subtypes expression in pituitary adenomas from operated acromegaly patients with clinical relapse and a complicated clinical course. Patients received pasireotide in the course of their disease. The predictive value of SSTR subtypes immunhistochemical analysis for the therapeutic response is discussed.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diagnostics

ISSN

2075-4418

e-ISSN

—

Svazek periodika

11

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

10

Strana od-do

"nestránkováno"

Kód UT WoS článku

000666940100001

EID výsledku v databázi Scopus

2-s2.0-85108283978